XTalks

JANUARY 17, 2023

The US Food and Drug Administration (FDA) granted approval to AstraZeneca’s Airsupra (albuterol/budesonide), formerly known as PT027, for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks in individuals aged 18 years and older who have asthma.

FDA Approval 77

FDA Approval Containment Allergies Drugs 77

XTalks

JULY 27, 2022

He showed the bottle label that seemed to indicate that it contains 444 servings of the product, at 60 calories per serving of about a tablespoon — a near mathematical impossibility. FDA-Approved? Shaw was recently fielding questions live on TikTok when someone asked her whether Pink Sauce was FDA-approved.

FDA Approval 94

FDA Approval Packaging Packaging Production 94

XTalks

SEPTEMBER 21, 2023

The company said it cannot “validate the safety or effectiveness of products claiming to contain tirzepatide that are not our own branded product.” Since the compounded versions of Mounjaro are not FDA approved, Lilly said they may expose patients to potentially serious health risks.

Pharmacy 59

Pharmacy FDA Approval Drugs Containment 59

XTalks

FEBRUARY 8, 2024

The top 15 diabetes drugs in 2023, according to 2022 sales data, reflect the current state of diabetes management and hint at the evolving needs and trends within this critical area of healthcare. Read on to learn more about the top 15 diabetes drugs in 2023, based on 2022 sales statistics. mL subcutaneous solution (2 mg/1.5

Sales 52

Sales Insulin FDA Approval Drugs 52

pharmaphorum

MARCH 3, 2021

The court ruled that AZ’s asserted claims in three of its patents protecting Symbicort, which is the mainstay of AZ’s respiratory diseases business unit with sales exceeding $2.7bn, are not invalid. Symbicort was first FDA-approved in 2006 as a treatment for asthma, followed by an extension to its label covering COPD in 2009.

Sales 52

Sales FDA Approval Containment Marketing 52

XTalks

NOVEMBER 9, 2022

Since Mounjaro’s May US Food and Drug Administration (FDA) approval, sales of the drug have skyrocketed beyond initial expectations owing to patient demand and a temporary shortage of Novo’s Ozempic. Sales of Ozempic were up by 28 percent in Q3 of 2022, driven by high demand for GLP-1-based diabetes treatments.

Insulin 93

Insulin Hormones FDA Approval Sales 93

XTalks

DECEMBER 5, 2023

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Augtyro (repotrectinib), marking a significant milestone for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC).

Protein 101

Protein FDA Approval Medicine Trials 101

XTalks

NOVEMBER 9, 2023

Eli Lilly is now fully armed on the GLP-1 front as it’s finally received US Food and Drug Administration (FDA) approval for Zepbound (tirzepatide), its obesity version of Mounjaro. The FDA approved Zepbound for chronic weight management in adults with obesity. Since its approval in May 2022, Mounjaro sales have hit $1.4

FDA Approval 59

FDA Approval Manufacturing Drugs Pharmacy 59

pharmaphorum

OCTOBER 10, 2022

It is already indicated for active booster immunisation against tetanus, diphtheria, and pertussis in those aged 10 years and over and it has also previously been approved for use in pregnancy to protect the mother. Following childbirth, the placebo recipients were then vaccinated with Boostrix.

Vaccination 52

Vaccination Vaccine FDA Approval Containment 52

pharmaphorum

NOVEMBER 1, 2021

Novartis has claimed FDA approval for one of its ‘wild card’ drugs – Scemblix – a first-in-class STAMP inhibitor for patients with previously-treated chronic myeloid leukaemia (CML). Tasigna made sales of $1.56 Scemblix could beef up Novartis’ CML portfolio, which remains a big earner for the company.

Drugs 115

Drugs FDA Approval Trials Containment 115

pharmaphorum

MARCH 4, 2021

billion for its FDA-approved dry eye drug Xiidra during the Japanese pharma’s merger with Shire in 2019, outlining the sales potential in this market niche. The pipeline for dry eye disease drugs is beginning to heat up, with two biotechs announcing key developments, aiming to disrupt a market led by Allergan and Novartis.

Gene Silencing 98

Gene Silencing FDA Approval Trials Marketing 98

Delveinsight

OCTOBER 1, 2021

Myasthenia Gravis Approved Therapies. The current Myasthenia Gravis therapeutics market has many FDA-approved drugs for the treatment of Myasthenia Gravis. Some of the approved drugs are: Prograf (Tacrolimus). Prograf is available for oral administration in the form of capsules (tacrolimus capsules USP) containing 0.5

Marketing 85

Marketing Antibody Drugs Sales 85

XTalks

JUNE 5, 2024

The FDA’s assessment comes over two years after Daily Harvest’s French Lentil + Leek Crumbles product containing tara flour sickened nearly 400 people. The study found that none of the GRAS notices voluntarily submitted to the FDA for review followed the draft guidance. Related: Food Additive Ban?

Protein 52

Protein Manufacturing Regulation Production 52

XTalks

JUNE 1, 2022

BONESUPPORT has recently received market authorization from the US Food and Drug Administration (FDA) for Cerament G, its bone graft with antibiotic elution. Xtalks learned more about BONESUPPORT and its first FDA-approved drug-device combination product Cerament G through an email interview with BONESUPPORT’s CEO Emil Billbäck.

Filler 96

Filler FDA Approval Production Marketing 96

Camargo

DECEMBER 9, 2020

If you are facing an FDA remote review, Camargo can help design a comprehensive approach in order to avoid such pitfalls. Approval of the Month: Alnylam to Use Value-Based Agreements for Ultra-rare Disease Treatment. In November, the FDA ended its Unapproved Drug Initiative. Unapproved Drug Initiative Ends.

Development 140

Development Production Drugs FDA Approval 140

XTalks

DECEMBER 5, 2022

The CBD prodrug will be going up against Jazz Pharma’s Epidiolex, the first FDA approved CBD drug formulation. Approved in 2018, Epidiolex is a CBD oral solution indicated for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, rare and severe forms of epilepsy, in patients two years of age and older.

Bioavailability 78

Bioavailability FDA Approval Trials Drugs 78

The Pharma Data

DECEMBER 28, 2020

Amphastar’s newly approved synthetic peptide product was determined by the FDA to be bioequivalent and therapeutically equivalent to Eli Lilly’s Glucagon Emergency Kit for Low Blood Sugar, which has a recombinant DNA (rDNA)-origin. However, not all forward-looking statements contain these words.

Bioequivalency 52

Bioequivalency Production Sales Marketing 52

Camargo

NOVEMBER 11, 2020

In October, Antares Pharma licensed Ferring Pharmaceuticals’ Nocdurna® (desmopressin acetate) sublingual tablet , which was approved in 2018 for the same indication as Noctiva and has a boxed warning highlighting the same risks. Presumably, Antares’ long-established 90-person urology sales force can achieve pull-thru of this drug product.

Development 242

Development Bioequivalency Generic Drugs Production 242

The Pharma Data

JANUARY 27, 2021

The collaboration with Bruker announced today will assess the suitability of the test as a professional-use in-vitro diagnostic (IVD) product for SARS-CoV-2 infection to run on Bruker’s MALDI-TOF instruments for sale in the UK and Europe. I look forward to updating the market when we have definitive clinical performance data.”.

Reagent 52

Reagent In-Vitro FDA Approval Development 52

XTalks

MARCH 12, 2024

“This approval is an important milestone for people living with obesity and cardiovascular disease, as the SELECT data demonstrated that Wegovy has the potential to prolong lives by addressing some of the leading causes of preventable deaths by reducing the risks of cardiovascular events.” The drug remains on the FDA’s drug shortages list.

Drugs 95

Drugs Production Trials FDA Approval 95

The Pharma Data

APRIL 27, 2021

Q1 2021 sales increase of 2.4% Specialty Care sales grew 15.3%, due to strong Dupixent ® performance (+45.6% General Medicines core assets grew 4.4%, while GBU sales were down 3.8%. Q1 2021 business EPS ( 1) growth at CER driven by efficiency and sales performance, supported by a one-time payment. IFRS net sales reported.

Sales 52

Sales Vaccination Vaccine Medicine 52

The Pharma Data

JUNE 17, 2022

The adalimumab reference medicine (Humira ®* ) was first approved with an adalimumab concentration of 50 mg/mL. 2,3 In 2015, the EMA and US FDA approved Humira ® HCF, which contains adalimumab at a concentration of 100 mg/mL. Our ambition is to be the world’s leading and most valued generics company.

Medicine 52

Medicine Generic Pharmaceutical FDA Approval Packaging 52

XTalks

MAY 1, 2023

Qalsody contains tofersen, an antisense oligonucleotide that specifically targets the mRNA made from mutated SODI genes to prevent the formation of toxic SOD1 proteins. At its peak sales, Qalsody is expected to generate around $300 million for Biogen. How Does Qalsody Work?

FDA Approval 62

FDA Approval Gene Genetics Protein 62

The Pharma Data

APRIL 4, 2023

The adalimumab reference medicine (Humira ® *) was first approved with an adalimumab concentration of 50 mg/mL. 1 In 2015, the EMA and US FDA approved Humira ® HCF, which contains adalimumab at a concentration of 100 mg/mL. Our ambition is to be the world’s leading and most valued generics company.

Medicine 40

Medicine Generic Pharmaceutical FDA Approval Marketing 40

XTalks

AUGUST 2, 2023

Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. Comirnaty was first approved by the US Food and Drug Administration (FDA) in August 2021 for individuals over the age of 16. It contains the antiviral medications nirmatrelvir and ritonavir. billion in 2022, a 23.43

Sales 85

Sales Manufacturing FDA Approval Life Science 85

pharmaphorum

OCTOBER 2, 2020

It’s the same indication targeted by Janssen with another medicine that drew inspiration from an illegal recreational drug – Spravato is an FDA-approved nasal spray containing esketamine, an isomer of ketamine.

Medicine 122

Medicine Life Science FDA Approval Development 122

FDA Law Blog

SEPTEMBER 30, 2024

Despite the removal of some of the most controversial proposals, the final rule still contains a variety of significant changes, which become effective on November 19, 2024. The preamble explains that manufacturers may use reasonable assumptions as to when a sale takes place (e.g., The most noteworthy are the following: 1.

Drugs 57

Drugs Manufacturing Regulation Production 57

The Pharma Data

NOVEMBER 3, 2020

DEXTENZA is FDA approved for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix’s first commercial drug product, DEXTENZA, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery. About DEXTENZA. Ocular Therapeutix, Inc.

Clinical Trials 52

Clinical Trials Clinical Trials Production FDA Approval 52

The Pharma Data

APRIL 15, 2022

GSK will account for the transaction as a business combination and expects it to be accretive to adjusted EPS in 2024, the expected first full year of momelotinib’s sales. Patients were symptomatic and anaemic and had been previously treated with an FDA-approved JAK inhibitor.

Sales 52

Sales Protein FDA Approval Trials 52

Camargo

MARCH 25, 2021

Its purpose is to stimulate the development of new drugs for rare pediatric diseases by offering additional incentives for obtaining FDA approval of such products beyond the incentives offered by the ODD program.

Production 130

Production Drugs In-Vitro Containment 130

The Pharma Data

DECEMBER 16, 2020

Aurinia will receive tiered royalties ranging from 10 to 20 percent (dependent on achievement of sale milestones) on net sales upon commercialization, along with additional milestone payments based on the attainment of certain annual sales by Otsuka. and has the potential to receive up to $50 million U.S. based in Japan.

Licensing 52

Licensing Licensing Development Sales 52

The Pharma Data

JANUARY 7, 2021

The Company also has granted to the underwriters a 30-day option to purchase up to an additional 2,100,000 shares of common stock at the Public Offering Price to cover over-allotments in the sales of the securities, if any. 333-233978), previously filed with the U.S. About Cerecor Inc. Forward-Looking Statements.

Clinical Development 52

Clinical Development Sales Development Containment 52

The Pharma Data

MAY 15, 2021

You can rest assured that it does not contain any dangerous stimulants or toxins, and more importantly, they are not habit forming. The product is made here, in the USA, in our FDA approved and GMP certified facility, under sterile, strict and precise standards. CLICKBANK® is a registered trademark of Click Sales, Inc.,

Production 52

Production Packaging Packaging Containment 52

The Pharma Data

DECEMBER 15, 2020

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

Containment 40

Containment Sales FDA Approval Development 40

The Pharma Data

JANUARY 24, 2021

This press release contains “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information contained in this press release is expressly qualified by this cautionary statement. Accordingly, readers should not place undue reliance on forward-looking information.

Drugs 52

Drugs Containment Development Clinical Development 52

XTalks

MARCH 15, 2023

FDA-approved ADHD-specific non-stimulants are a relatively newer class of medication designed to treat ADHD that have much fewer side effects than stimulants. Strattera’s active ingredient is the SNRI atomoxetine hydrochloride while Qelbree contains viloxazine hydrochloride, a serotonin-norepinephrine modulating agent (also a SNRI).

Drugs 93

Drugs Sales Trials Marketing 93

FDA Law Blog

JANUARY 11, 2022

In accordance with the statutory “section viii” provision, FDA approved Hikma’s generic product referencing Vascepa in May 2020 omitting information pertaining to the patented CV indication. The procedural background of Amarin v. Hikma (unlike that of GSK v.

FDA Approval 52

FDA Approval Production Branding Drugs 52